Nice — below is a sourced market brief for the Pen Needles Market with company references that include numeric values where available, followed by the sections you requested. I pulled recent company filings, press and market-research reports and cite the most load-bearing items so you can verify quickly.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Pen Needles market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Pen Needles market.

Read complete report at: https://www.thebrainyinsights.com/report/pen-needles-market-12878

Company references (company → public value / metric)
Embecta Corp. — pen-needles accounted for ≈USD 844M of net sales in fiscal 2024 (pen needles ≈75% of total net sales reported for FY2024). Embecta remains the world’s largest dedicated pen-needle & syringe manufacturer.

Becton, Dickinson & Company (BD) — FY2024 revenue: USD 20.2B (BD is a major global supplier of drug-delivery devices; BD’s legacy diabetes unit created standalone players like Embecta).

Ypsomed — Diabetes Care segment (pen-needle/pen systems business before divestiture) reported CHF 236.9M sales in FY 2024/25 (company disclosure; note Ypsomed sold its pen-needle/BGM business in 2024).

Owen Mumford — established UK injection-device manufacturer and pen-needle supplier (private company; public responsibility reports and corporate profiles document scale and product focus). Exact product-line revenue is not disclosed publicly in itemised form.

Market share / production scale (industry) — press reporting: the global leading manufacturers produce billions of needles annually (Embecta reported production scale of ~8 billion syringes & pen needles annually in press coverage).

(Companies often report segment or corporate revenue rather than product-level numbers for pen needles specifically; I focused on the clearest public figures and high-quality press/filings where available.)

Market size & recent estimates (top-line)
Representative market estimates (varies by source / definition):

Grand View Research: USD 4.1B (2024); projected to reach ~USD 7.8B by 2030 (CAGR ≈10.1%).

Fortune Business Insights: USD 2.28B (2024) with growth to USD 3.89B by 2032 (CAGR ≈7.0%).

MarketsandMarkets / Mordor / Allied / other analysts provide nearby baselines (USD ~1.7–4.4B in the early-2020s depending on scope) and generally project mid-to-high single-digit to low-double-digit CAGRs through the 2020s.

(Variation reflects differences in scope — e.g., whether the report counts only disposable pen-needles, adds safety-engineered devices, or includes related injection accessories.)

Recent Developments
Strong, steady demand driven by diabetes incidence and insulin pen adoption — rising diabetes prevalence and global shift to pen injectors (vs vials/syringes) support sustained pen-needle volumes.

Corporate restructuring & spin-outs — BD’s diabetes legacy split produced stand-alone firms (Embecta) and several suppliers adjusted portfolios (Ypsomed sold its pen-needle business in 2024), reshaping competitive dynamics.

Safety-engineered pen needles & regulatory focus — accelerated uptake of safety pen-needles (needle-retraction or shielded designs) in many markets for sharps-injury reduction and compliance. Market reports flag safety devices as one of the fastest growing segments.

Drivers
Rising diabetes prevalence (global T1/T2 patients and longer treatment horizons) — the most fundamental demand driver.

Pen injector preference & product stickiness — insulin pens (and increasing use of GLP-1/other injectable therapies delivered by pens) produce recurring pen-needle purchases.

Regulatory & workplace safety requirements — adoption of safety pen needles in hospitals, clinics and some home-care programs.

Restraints
Impact of changing therapeutic mix (GLP-1 / weight-loss drugs) — some press reports flag that surging GLP-1 adoption could change diabetes medicine profiles and thus influence long-term insulin demand in certain markets; this is an evolving risk/uncertainty.

Pricing pressure & commoditization — pen needles are a high-volume, low-unit-price product; manufacturers face price competition and margin pressure, particularly in commoditised geographies.

Regulatory barriers to safety device adoption in some emerging markets — cost and procurement practices slow uptake of higher-cost safety-engineered pen needles.

Regional segmentation analysis
North America — large share (high per-capita insulin use, established reimbursement/retail channels); safety devices strong. U.S. market (per Grand View) generated ~USD 958M in 2024 (U.S. market snapshot).

Europe — significant market for safety devices and disposable pen needles; many countries moving faster on safety adoption.

Asia-Pacific — fastest growth prospects driven by rising diabetes prevalence, larger population base and improving access to insulin pens (APAC often shows the highest CAGR in market reports).

Emerging Trends
Shift toward safety-engineered pen needles (retractable/shielded) to reduce needlestick injuries.

Consolidation & vertical integration — M&A, spin-outs and strategic deals reshaping supplier footprints (examples: BD → Embecta split; Ypsomed divestiture).

Adjacency to injectable platform growth — growth of other chronic injectable therapies (GLP-1s, biologics) that may broaden pen-needle use cases beyond insulin.

Top Use Cases
Insulin administration (T1 & T2 diabetes) — dominant use case (largest share of volume/revenue).

Other subcutaneous therapies delivered by pens — GLP-1s, some biologics and growth-hormone therapies where pen formats are used.

Clinical / institutional use (safety devices for sharps-injury prevention) — hospitals and clinics adopting safety pen needles.

Major Challenges
Demonstrating differentiated value vs low-cost commodity needles — innovation must clearly lower sharps injuries or improve patient experience to command premium pricing.

Supply chain & capacity constraints for high volumes — manufacturers must maintain very large, reliable production to meet recurring global demand.

Attractive Opportunities
Safety-needle conversions in emerging markets — programs to replace conventional needles with safety devices (public-health, hospital procurement).

Adjacency into pen systems & combination offerings — suppliers that can bundle pens, needles, disposables and digital adherence services can increase wallet share.

Outsourced manufacturing / contract production — scale players and contract manufacturers can capture demand from brand owners seeking lower capital intensity.

Key factors of market expansion
Diabetes prevalence & treatment penetration (insulin & injectable therapies).

Regulatory push for safety devices & institutional procurement policies.

Penetration of pen injectors (vs vials/syringes) across emerging markets, supported by distribution and reimbursement improvements.

Sources — (selected, high-impact)
Grand View Research (market size & country/U.S. snapshot).
Fortune Business Insights / MarketsandMarkets / Mordor Intelligence / Allied / Future Market Insights (alternate forecasts & CAGR scenarios).
Embecta FY2024 filings & press releases (pen-needle revenue detail).
BD FY2024 results & press.
FT / press coverage on production scale and strategic motions (Embecta production scale ~8bn needles; market structure).

If you’d like, I can immediately convert this into one of the following — tell me which and I’ll generate it now with the cited sources included:

One-page vendor table (company | most recent revenue / pen-needle metric | FY year | 1-line note + citation).

2-slide investor memo (TAM scenarios, 4 company snapshots, 3 strategic risks).

Regional demand spreadsheet (APAC / NA / EU / LatAm / RoW) with 2024 baseline and 2025–2030 CAGR scenarios from 2 different analyst sources.

Which deliverable do you want me to produce now?